Adenoma
A benign epithelial tumor with a glandular organization.
Subtype terms (20)
More specific conditions that are subtypes of Adenoma in the MeSH hierarchy.
- ACTH-Secreting Pituitary Adenoma
1 drug approved
- Adenoma, Acidophil
- Adenoma, Basophil
- Adenoma, Bile Duct
2 drugs experimental
- Adenoma, Chromophobe
- Adenoma, Islet Cell
21 drugs (20 approved, 1 experimental)
- Adenoma, Liver Cell
3 drugs (2 approved, 1 experimental)
- Adenoma, Oxyphilic
3 drugs (2 approved, 1 experimental)
- Adenoma, Pleomorphic
2 drugs approved
- Adenoma, Sweat Gland
- Adenomatoid Tumor
- Adenomatosis, Pulmonary
- Adenomatous Polyps
10 drugs (8 approved, 2 experimental)
- Adenoma, Villous
- Adrenal Rest Tumor
- Apudoma
1 drug approved
- Cystadenoma
- Growth Hormone-Secreting Pituitary Adenoma
1 drug approved
- Mesothelioma
214 drugs (85 approved, 129 experimental)
- Prolactinoma
8 drugs (7 approved, 1 experimental)
Drugs by status
Approved for this indication (3)
Phase 4 trials (4)
Phase 2 trials (6)
Phase 1 trials (6)
Organizations
Organization Involved with Phase 4 Indications (12)
Organization Involved with Phase 3 Indications (28)
- Axcan
- Merck
- Pfizer
- Sanofi-Synthelabo
- Cancer Prevention Pharmaceuticals, Inc.
- Corcept Therapeutics
- Nihon Pharmaceutical Co., Ltd
- Colotech A/S
- National Cancer Institute (NCI)
- Dartmouth University
- Korea University
- Norwegian University of Science and Technology
- Pierre and Marie Curie University
- Radboud University
- Seth Gordhandas Sunderdas Medical College
- Southwest Oncology Group
- Aalborg University
- University of California, Irvine
- University of California, San Francisco
- Federal University of Rio de Janeiro
- Government of China
- University of Sao Paulo
- University of Paris
- Dutch Cancer Society
- Sungkyunkwan University
- Government of France
- People's Liberation Army of China
- Chinese Academy of Medical Sciences
Organization Involved with Phase 2 Indications (30)
- Amgen
- Morphotek
- Novartis
- Pharmacia
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Pennsylvania
- University of Pittsburgh
- Cedars-Sinai Medical Center
- Cornell University
- Harvard University
- Emory University
- Deutsche Krebshilfe e.V.
- Northwestern University
- Ohio State University
- Utrecht University
- Mayo Clinic
- Fudan University
- University of Copenhagen
- University of Ulm
- Department of Defense
- Martin Luther University
- University of Alabama, Birmingham
- Department of Veteran Affairs
- Koordinierungszentren für Klinische Studien bzw. Zentren für klinische Studien
- University of Caen-Normandie
- Region Zealand
- Reponex Pharmaceuticals A/S
- Tiburio Therapeutics
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (22)
- Huazhong University of Science and Technology
- Seoul National University
- Texas Tech University
- University of Padova
- University of Puerto Rico
- Yonsei University
- Capital Medical University
- Fujian Medical University
- Istanbul University
- Istituti Ospitalieri di Cremona
- Wenzhou Medical University
- Vanderbilt University
- Zhejiang University
- Shandong University
- Southeast University
- University of Minnesota
- Paris Descartes University
- Humanitas University
- Nuovo Regina Margherita Hospital
- University of Lyon
- Washington University in St. Louis
- China Medical University